Compare NMM & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMM | ALMR |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2007 | 2026 |
| Metric | NMM | ALMR |
|---|---|---|
| Price | $85.40 | $31.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $110.25 | $37.00 |
| AVG Volume (30 Days) | 138.9K | ★ 767.3K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.68 | $64.80 |
| Revenue Next Year | $5.27 | $37.27 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.76 | $21.58 |
| 52 Week High | $97.00 | $39.61 |
| Indicator | NMM | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 54.18 |
| Support Level | $69.21 | $23.52 |
| Resistance Level | $92.02 | $37.81 |
| Average True Range (ATR) | 2.64 | 2.60 |
| MACD | -0.47 | -0.02 |
| Stochastic Oscillator | 32.40 | 63.67 |
Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.